Provided by Tiger Trade Technology Pte. Ltd.

Incyte

117.14
-4.2100-3.47%
Post-market: 117.00-0.1360-0.12%19:08 EDT
Volume:2.36M
Turnover:279.69M
Market Cap:23.74B
PE:14.92
High:121.22
Open:120.47
Low:117.00
Close:121.35
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.60
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.74
PE(LYR):18.27

Loading ...

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
2 hours ago

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
3 hours ago

Incyte Price Target Raised to $128.00/Share from $116.00 by Wells Fargo

Dow Jones
·
Yesterday

Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating

MT Newswires Live
·
Yesterday

Analysts Offer Insights on NA Companies: Micron (MU), Exxon Mobil (XOM) and Incyte (INCY)

TIPRANKS
·
Yesterday

Halozyme Appoints Jim Daly to Board of Directors

Reuters
·
Yesterday

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 30

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Incyte management to meet with Oppenheimer

TIPRANKS
·
Sep 29

MiniMed Names Sheila Denton General Counsel, Corporate Secretary

Reuters
·
Sep 28

Mirum Rises on FDA Nod for Rare Bone Disorder Drug

Reuters
·
Sep 28

Incyte Price Target Raised to $152.00/Share from $150.00 by HC Wainwright & Co.

Dow Jones
·
Sep 28

Incyte Corporation : H.c. Wainwright Raises Target Price to $152 from $150

THOMSON REUTERS
·
Sep 28

JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating

MT Newswires Live
·
Sep 28

Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA

MT Newswires Live
·
Sep 28

Incyte : JP Morgan Raises Target Price to $123 from $120

THOMSON REUTERS
·
Sep 28

Incyte (INCY) Gets a Hold from Bernstein

TIPRANKS
·
Sep 26

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (Zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Sep 26

FDA approves Incyte’s Atebrioz for fibrodysplasia ossificans progressiva

TIPRANKS
·
Sep 26

US FDA Approves Mirum's Drug for Rare Bone Disorder

Reuters
·
Sep 26